VolitionRx's Lung Cancer Risk Stratification Data Highlighted at ELCC 2026
Event summary
- VolitionRx presented an abstract at ELCC 2026 demonstrating Nu.Q® Cancer assays' ability to stratify lung cancer patients by risk.
- Study found high H3K27Me3-nucleosome levels predicted poorer survival outcomes in Non Small Cell Lung Cancer patients.
- Nu.Q® technology aims to support treatment decision-making and monitoring throughout patient journey.
- Research conducted in collaboration with National Taiwan University Hospital and Lyon.
The big picture
VolitionRx's presentation at ELCC 2026 underscores the growing importance of liquid biopsy technologies in precision oncology. The ability to stratify lung cancer patients by risk using simple blood tests aligns with broader industry trends toward personalized medicine and earlier cancer detection. The company's focus on epigenetics positions it in a competitive but rapidly evolving segment of the biotech market, where successful commercialization could significantly impact patient outcomes and drive revenue growth.
What we're watching
- Clinical Adoption
- How quickly Nu.Q® Cancer assays will be integrated into clinical practice for lung cancer management.
- Regulatory Pathway
- The pace at which VolitionRx can secure necessary regulatory clearances for its diagnostic technology.
- Commercialization Strategy
- Whether VolitionRx can successfully commercialize its technology through licensing or distribution agreements.
Related topics